Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789606 · ClinicalTrials.gov registry record · Phase 3
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,083
- Enrollment target
NCT01789606: Completed Phase 3 study, sponsored by Pfizer.
NCT01789606 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,083 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01789606, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,083 participants
- Enrollment target
Study Summary
A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.
Primary Outcome
Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of less than (\<) 6 hours, if left untreated.
Interventions
- DRUG Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,083 participants |
| Start Date | 2012-09-24 |
| Est. Completion | 2013-06-03 |
| Phase | Phase 3 |
What the finished NCT01789606 record still lists
NCT01789606 is an interventional study that assigns participants to a tested intervention. Its 1,083 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 1 intervention - of which Ibuprofen 600 mg Immediate Release/Extended Release Caplet is the first listed.
NCT01789606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01789606 about?
NCT01789606 is a clinical study titled "Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet". A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.
What is the current status of trial NCT01789606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,083 participants. The study started on 2012-09-24. Estimated completion is 2013-06-03.
What interventions are being tested in trial NCT01789606?
The interventions under investigation include: Ibuprofen 600 mg Immediate Release/Extended Release Caplet (DRUG).
Who is sponsoring clinical trial NCT01789606?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01789606's enrollment target sits among peer trials
1,083 269th of 2000 higher than 1,732 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI